Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial
Hepatocellular Carcinoma Resectable
About this trial
This is an interventional treatment trial for Hepatocellular Carcinoma Resectable
Eligibility Criteria
Inclusion Criteria: Undergone radical surgical resection. Aged 18-75. Patients voluntarily cooperated with the study and signed an informed consent form. Histopathologically diagnosed hepatocellular carcinoma. Patients with R0 resection confirmed by imaging and pathology (no residual lesions and complete tumor resection after radical surgery). Child-Pugh score of 5-7 (A or B), patients with a score of 7 must be free of ascites. ECOG physical fitness status score of 0-1. No serious heart, lung, or renal dysfunction Exclusion Criteria: Unable to provide specimens for PDOX testing. Patients with recurrent liver cancer. Developing two or more types of tumors simultaneously. Patients with existing extrahepatic distant metastases. Treatment with other experimental drugs or other interventions after radical resection. Patients with other malignant tumors that have not been cured within 5 years. Patients with non-radical resections (R1 and R2 resections). Patients with residual or recurrent lesions detected on imaging within 1-2 months after surgery. Died within 1 month after surgery.
Sites / Locations
- Zhujiang Hospital of Southern Medical UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
the test group
the control group
The test group received postoperative conventional treatment combined with precise transarterial chemoembolization based on PDOX results. Precise transarterial chemoembolization at 1-month intervals for 2 months after surgery.
The control group received postoperative conventional treatment combined with Empirical transarterial chemoembolization with Doxorubicin. Empirical transarterial chemoembolization at 1-month intervals for 2 months after surgery.